MARKET

REPL

REPL

Replimune Group
NASDAQ

Real-time Quotes | Nasdaq Last Sale

21.37
-0.08
-0.37%
Closed 16:00 08/05 EDT
OPEN
21.75
PREV CLOSE
21.45
HIGH
22.00
LOW
21.18
VOLUME
158.27K
TURNOVER
--
52 WEEK HIGH
26.22
52 WEEK LOW
8.58
MARKET CAP
864.59M
P/E (TTM)
-14.0324
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average REPL stock price target is 29.43 with a high estimate of 40.00 and a low estimate of 25.00.

EPS

REPL News

More
Replimune to Present at Two Upcoming Investor Conferences
WOBURN, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL) a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that members from the Replimune management team will
GlobeNewswire · 2d ago
Replimune Appoints Andrea Pirzkall, M.D. as Chief Medical Officer
WOBURN, Mass., July 22, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the strengthening of its executive team with the app
GlobeNewswire · 07/22 11:00
HC Wainwright & Co. Downgrades Replimune Group to Neutral, Announces $25 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Replimune Group (NASDAQ:REPL) from Buy to Neutral and announces $25 price target.
Benzinga · 07/01 11:03
The Daily Biotech Pulse: Verrica Flags Potential Regulatory Delay, Back-To-Back FDA Approvals For Merck's Keytruda, OncoCyte Stalls Lung Nodule Malignancy Test
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29)
Benzinga · 06/30 11:41
The Daily Biotech Pulse: Chiasma, Heron Await FDA Decisions, DBV Restructures, 3 Biopharmas Make Wall Street Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 25)
Benzinga · 06/26 12:28
Replimune Group, Inc. (REPL): Hedge Funds Are Reducing Exposure
Insider Monkey · 06/22 19:27
Replimune to Participate at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference
GlobeNewswire · 06/17 13:00
Replimune (REPL) Looks Good: Stock Adds 5.8% in Session
Zacks · 06/11 13:47

Industry

Biotechnology & Medical Research
+0.18%
Pharmaceuticals & Medical Research
+0.35%

Hot Stocks

Symbol
Price
%Change

About REPL

Replimune Group, Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP, RP2, and RP3. The Company is focused on Phase 1/2 clinical trial with its lead product candidate, RP1, in approximately 150 patients with a range of solid tumors.
More

Webull offers kinds of Replimune Group Inc stock information, including NASDAQ:REPL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, REPL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading REPL stock methods without spending real money on the virtual paper trading platform.